INTRODUCTION U
NAIDS ESTIMATES that in 2001, 5 million new HIV infections occurred worldwide. 1 While the majority of existing and new infections occur in sub-Saharan Africa, 1 the Indian government estimates that as many as 3.8 million of its citizens were HIV-positive at the end of 2000. 2, 3 Others project that by 2005, a staggering 37 million people in India may become HIV infected, 3 along with 10 million people in China by 2010. 4 Most HIV infections worldwide occur via sexual transmission. Preventing or at least reducing sexual transmission of HIV is therefore a top priority.
Women are often not in a position to negotiate the use of condoms, leading many to consider the use of microbicides the most promising means of reducing the sexual transmission of HIV. A microbicide is, "any topical agent that inactivates or kills the pathogen, physically blocks its attachment to susceptible target cells, supports natural defenses, or prevents its more widespread dissemination from target cells." 5 A microbicide might take the form of a cream, foam, gel, etc., and would ideally be undetectable to the sex partner, and would not detract from sexual pleasure. The potential impact of even a partly effective microbicide is startling: researchers from the London School of Hygiene and Tropical Medicine calculate that over 3 years, 2.5 million infections could be averted, while $2.7 billion in health care costs and more than $1 billion in productivity gains could be saved if a microbicide that is 60% efficacious against HIV were used by 20% of women in half of all sex acts that do not involve a condom. 6 The development of microbicides has so far not garnered as much financial support as vaccine or pharmaceutical research. Anna Forbes, from the Global Campaign for Microbicides, estimates that $100 million are needed each year to advance microbicide candidates from the laboratory through clinical trials, yet the National Institutes of Health spent just $47. 
CONFERENCE SUMMARY
In some ways the conceptually simplest microbicide option consists of a physical barrier. Physical barriers to HIV would prevent viral transmission (both male to female and female to male) but may have negative consequences for each partner of women with multiple sex partners. The vagina could act as a depository for any virus in the ejaculate of one male and could infect the next male partner, even in the absence of infection in the female (in much the same way as a female condom used more than once could enhance the risk of transmission to the next male partner). Also, a microbicide that does not kill or permanently inactivate the virus might lose efficacy over time because of degradation of the formulation or leakage, leaving any residual surviving virus perfectly placed to infect the genital tract. At the very least then, an effective microbicide must contain an active anti-HIV agent that either kills or permanently disables the virus, in addition to any barrier function.
Because it is difficult to envision how a microbicide might abrogate HIV infection once integration has taken place, the active agent in a microbicide should target preintegration events in the viral life cycle. Targets of pharmacologic action are thus limited to prebinding, binding, fusion, entry, uncoating, and reverse transcription. Almost all microbicide candidates currently under consideration prevent viral entry. These include surfactants, sulfated and other charged polymers, natural defense enhancers, and binding and fusion inhibitors. Products that act postentry include the nucleoside and nonnucleoside reverse transcriptase inhibitors.
One of the fundamental difficulties in the development of an effective anti-HIV agent for use in a microbicide has been the discovery of pharmacologic agents that are simultaneously virucidal and nontoxic to the mucosa. The recent failure of nonoxynol-9 (N-9) as a potential microbicide candidate, as reported at the 2000 International AIDS Conference 8 highlights the importance of the toxicity profile of any potential pharmacologic agent or formulation. N-9 has been used for at least 30 years as a spermicide, and may also be active against a variety of sexually transmitted infections (STIs). 9 Some in vitro studies have suggested possible anti-HIV activity of N-9.
10 David Wilkinson, of the University of Adelaide in Australia, conducted a meta-analysis of nine randomized controlled clinical trials of N-9 in which new HIV infection, STIs, or genital ulcers were primary endpoints. The analysis revealed a slightly, but not significantly, higher risk of HIV infection with N-9 relative to placebo, and no protection against a range of STIs except chlamydia (relative risk, 0.86). However, N-9 was associated with a significantly enhanced risk of genital ulcers (relative risk, 1.15). 11 In other words, not only is there no basis for recommending the use of N-9 as a microbicide, there may actually be the risk of increased harm.
Several other surfactants are currently under investigation as microbicides, including C31G, benzalkonium chloride, octoxynol-9, polybiguanides, sodium lauryl sulfate (SLS), and sodium dodecyl sulfate (SDS). Surfactants are surface active agents that disrupt viral and other lipid membranes and can thus target cellfree or cell-associated virus before interaction with the target cell. As such, surfactants run an inherently higher risk of cellular toxicity than some other pharmacologic agents. Cellular toxicity in turn is associated with genital ulceration and thereby an increased risk of HIV transmission (because of enhanced access of the virus to the blood stream or to invading leukocytes). 12 It is worth noting that although avoiding cytotoxicity is almost universally recommended, a selectively toxic microbicide that would target infected seminal leukocytes could be an invaluable tool for preventing transmission of cell-associated HIV. However, it is difficult to envision how such an agent could be produced with a sufficiently high therapeutic index.
Two surfactants other than N-9 were discussed at the conference, C31G (marketed as Savvy™, Biosyn, Huntingdon Valley, PA) and sodium lauryl sulfate (SLS). C31G is an amphoteric surfactant marketed by Biosyn. It has faster diffusion into cervical mucus and less toxicity to vaginal keratinocytes than N-9, has in vitro activity against several STIs and is spermicidal. 13 Christine Mauck, from CONRAD, reported on a phase I trial of C31G in 64 healthy women to determine irritation and toxicity. Three doses were applied once per day for 7 days, then twice per day for a further 7 days. Only the highest dose (1.7%) was associated with a level of irritation similar to that seen with N-9, and twice-per-day application of the lower doses did not increase irritation. There were few changes in vaginal microflora, and one-half to two-thirds of study participants found the product acceptable. 13 Michel Bergeron, from the University of Laval in Quebec, described results from a phase I study using the Invisible Condom™ (University of Laval, Laval, Quebec), a thermoreversible gel that is liquid at room temperature and solid at body temperature. The gel contains SLS and has previously been shown to have in vitro and in vivo activity against HIV and other STIs. This formulation acts as both a physical and chemical barrier to pathogens, where the gel traps virus particles and the SLS interferes with the viral maturation process. Women applied the gel and engaged in sexual intercourse with their regular sex partners. There were no adverse changes in Lactobacillus or vaginal pH, and the gel was well distributed. The acidic pH of the vagina (approximately 4.0-5.0) is maintained in part by lactobacilli in the normal vaginal flora and helps to inhibit pathogens including HIV. After a total of 602 applications, only 5 adverse events were reported, 4 of which were mild, 1 moderate. Male partners reported no serious or definite adverse events. Interestingly, women in the study started with slightly abnormal Lactobacillus on average. Vaginal flora was normalized during use of the gel but returned to 23% abnormal 2 weeks after termination of the use of the gel. 14 Three sulfated polymers were discussed at the conference: naphthalene sulfonate polymer (PRO2000), carrageenan (Carraguard™, Population Council, New York, NY) and dextrin sulfate (Emmelle™, ML Laboratories, Warrington, UK). Sulfated polymers carry charges and interfere with coreceptor binding sites on gp120. For example, dextrin sulfate binds the V3 loop, a highly variable region of the HIV envelope glycoprotein gp120 that subserves the attachment of the virus to coreceptors (either CCR5 or CXCR4) on the host cell. But as explained by Quentin Sattentau of the Imperial College of Science, Technology and Medicine in London, the charge on the V3 loop varies substantially between viral isolates and tends to be almost neutral in primary isolates, meaning that substantially more compound might be needed to inhibit the binding of primary isolates to CCR5. In addition, the charge on the CXCR4 binding region is much stronger than that for the CCR5 binding site, leading to the prediction that these compounds might be more effective against X4 than R5 strains of virus. 15 Partial results from a phase 1 trial of PRO2000 were reported by Charles Lacey from the Imperial College of Science, Technology and Medicine, London. Women applied gel daily for 2 weeks, and researchers measured levels of the active ingredient in both cervico-vaginal lavage and blood plasma samples. No compound was detected in any plasma samples. At both doses tested, lavage samples taken 2 hours after product application exceeded concentrations shown to be anti-HIV in vitro. Twelve hours after application, only the higher dose (4%) exceeded the recommended concentration. 16 Carraguard™ or carrageenan, derived from red seaweed and commonly used as a thickening agent in ice cream and soups, is the best known and most advanced current microbicide candidate. It has proceeded successfully through phase 2 trials in Africa and Asia, and is expected to enter phase 3 trials soon. Two researchers, Nicol Coetzee from the University of Cape Town, South Africa, and Peter Kilmarx, from the CDC, Thailand, reported safety data from several hundred women who had used Carraguard™ vs placebo gel. 17, 18 In general, women found each gel acceptable and reported in some cases an enhancement of sexual pleasure. Use of the gel was much higher in Thailand, where it was used in more than 90% of sex acts, 17 compared to 75% or greater use in 60% of sex acts in Africa. 18 Anti-HIV effective-ness has not yet been evaluated, although the South African arm of the study yielded an equal number of seroconversions in each study group. Dextrin sulfate was evaluated in two studies, one in women and one in men. Michael Bukenya, from the Medical Research Council in Uganda, reported results from the first 35 women in a phase 2 trial in Kampala designed to determine safety and acceptability. Of the 25 women who used the gel (10 women were observation-only subjects), 3 reported thirst of unknown etiology and 4 reported vaginal itching. There were no clinical epithelial adverse events, including abnormal symptomology, epithelial disruptions, changes in vaginal flora or systemic toxicity. 19 Penile application studies are conducted to determine the extent of potential toxicity and irritation to the male partners of women using a particular microbicide. Vicky Jespers, of the Institute of Tropical Medicine in Belgium, reported that men who applied 4% dextrin sulfate to the penis daily for 14 days (leaving the gel in place for at least 6 hours) experienced minimal adverse events and concluded that the gel was well tolerated and accepted. 20 One difficulty reported in this and other studies of male safety and acceptability involves ensuring compliance with the requirement that men abstain from sex and masturbation for the study period. In this study, only 25% of males reported compliance.
Different classes of active compounds aim to maintain or enhance the natural defenses of the vagina against HIV infection. The pH of the vagina, approximately 4.0-5.0, is sufficient to counteract HIV but is neutralized by ejaculate, which is alkaline. Acid-buffering gels, such as BufferGel™ (ReProtect, Baltimore, MD) and Acidform, maintain the acidity of the vagina in the face of semen and thereby guard the epithelium from infection. Marianne Callahan, from CONRAD, described a safety and acceptability study in circumcised and uncircumcised men in which BufferGel™, or one of two sulfated polymers (PRO200 or cellulose sulfate), were applied to the penis for 7 days and left overnight. BufferGel™ was associated with minor adverse events in approximately 5% of study participants, and 90% of these study participants reported that they would not object to the use of this product by a sex partner. The most serious adverse event in the study (with PRO2000), involving laceration plus complications, resulted from a study participant holding the gel-dispensing tube too close to his penis. 21 One other means of maintaining natural vaginal defenses against pathogens involves the use of lactobacillus suppositories. Sharon Hillier, from the University of Pittsburgh, reported on the use of a Lactobacillus crispatus suppository known as CTV-05 to maintain normal vaginal flora. These lactobacillus suppositories are popularly, if inaccurately, known as "vaginal vitamin." The presence of normal flora is thought to decrease the incidence of bacterial vaginosis, gonorrhea and HIV. Only 50% of women in the United States have hydrogen peroxide-producing lactobacilli after the treatment of bacterial vaginosis. This product is not intended for use during sex but rather for the treatment of STIs and thereby the possible reduction of the incidence of HIV and other STIs. Women were recruited from a STI treatment clinic and received extensive counseling regarding safer sex practices. Despite this, there was a high rate of new STI infection (5% in 1 month), and women reported high risk behaviors such as anal sex (7%-9%) and douching, and a low rate of condom use (approximately 50%). 22 The other main class of microbicide agents under investigation are the binding/fusion/ entry inhibitors. Several are already being tested as therapeutics, including agents acting at each of the main coreceptors (CCR5 and CXCR4) as well as on CD4, gp120, and gp41. Some of the most interesting discussions at the conference revolved around the development of this kind of microbicide.
Edward Berger, from the National Institute of Allergy and Infectious Diseases (NIAID), described his design of a neutralizing protein made from 17b, which binds the coreceptor binding site on gp120, conjugated to soluble CD4 (sCD4-17b). 23 The presence of the sCD4 brings gp120 into the correct conformation to allow binding by 17b before apposition to the target cell. This novel protein neutralizes HIV better than the most effective broadly neutralizing antibodies currently under study, includ-ing 2F5, 2G12, and b12. While many HIV isolates can be completely neutralized by sCD4-17b, other isolates were completed unaffected. Berger postulated that the lack of activity against some isolates might have been because of the design of the linker between sCD4 and 17b, which was based on the only available crystal structure of gp120, derived from only one isolate. He suggested the possible application of sCD4-17b as a topical microbicide, or its expression in lactobacillus as a secreted surface-expressed protein that could be used as a microbicide. This could be used as "viral fly paper" by adsorbing free virus.
Paolo Lusso, of Department of Biological and Technical Research (DIBIT)-San Raffaele Scientific Institute, Italy, asked whether it would be possible to rationally design a CCR5 inhibitor, given the difficulties associated with elucidating its structure (because the transmembrane segments are profoundly hydrophobic). Instead he suggested learning from the structure of RANTES, the evolutionarily optimized ligand of CCR5. He made several peptides mimicking RANTES and was able to uncouple CCR5 receptor interaction from the blocking of HIV, leading to the generation of a compound that is not a receptor agonist and is therefore noninflammatory. 24 The L and D peptides are equally effective, and because D peptides are less susceptible to native proteins, this class of compounds could conceivably be developed for use as a microbicide. As yet, these peptides are not maximally effective, possibly because they are linear and do not adopt the appropriate three-dimensional structure in solution. Lusso will continue to modify and improve these compounds.
The success of any of the compounds presently being developed depends to a large extent on particulars of HIV transmission that are to a great extent not yet understood. For example, is transmission primary achieved via cell-free or cell-associated virus? Which are the first cells to be infected? Does infection first take place at the epithelium, subepithelium stromal layers, lymph nodes? Would it be best to target the virus or the cell? These questions were posed by John Moore of Cornell University, who described experiments using a monoclonal antibody alone or conjugated to virus as a proof-of-principle to investigate whether fusion inhibitors could theoretically work as microbicides in HIV. For his experiments, Moore used a SHIV, an engineered virus consisting of a simian immunodeficiency virus (SIV) core with an HIV envelope. Macaques were exposed to SHIV-162P4, an R5 tropic (CCR5 receptorutilizing) virus either conjugated to b12 or after 25 mg/kg b12 intravenously. In both cases, b12 was protective against viral infection, demonstrating that fusion inhibitors, or b12 itself, could serve as a microbicide. 25 Inexpensive production of b12 might be achieved by the use of plantibody technology.
Although no researchers reported specifically on the use of plantibodies at the conference, they represent a promising way of delivering antipathogen antibodies to the vagina in the form of a microbicide, and could neutralize the pathogen before infection takes place. Plantibodies are monoclonal antibodies that are grown in plants, normally corn, using a process that allows the inexpensive production of large amounts of antibody. Plantibodies are in development by Epicyte Pharmaceutical Inc., and we can expect to hear more about them in the future. 26 Another of the uncertainties surrounding HIV transmission concerns the preferential transmission of R5 rather than X4 (CXCR4 receptor-utilizing) virus. This question was also addressed by Leonid Margolis, 27 along with issues relating to the switch from R5 virus to a X4 virus (often presaging AIDS), and the speed of progression to AIDS with X4 virus. X4 virus severely depletes T cells, whereas R5 results in only relatively mild T-cell depletion. The answer to why this is the case lies not in the virus but in the infected tissue. Most T cells are CXCR4 1 (,80%), whereas only few are CCR5 1 (,6%). Approximately 10% of T cells are X4/R5 1 . In other words, X4 and R5 tropic viruses each kill their respective targets equally well, but because there are so many more CXCR4 1 cells, these are more severely affected by the presence of X4 virus. Would this not suggest that dual tropic virus would result in the death of T cells at an even faster rate than monotropic virus? We know this is not the case. For example, AMD3100, a CXCR4 antagonist, completely inhibits SHIV-89.6P, whereas RANTES has almost no effect on this dual tropic virus. In other words, dual tropic viruses act as though monotropic in tissue.
It is clear that a better understanding of the process of HIV infection via the mucosa will assist in the development of an effective microbicide. Charles Wira, of the Dartmouth Medical School, brought the audience up to date on vaginal immunity. Of all cells in the female reproductive tract, a high percentage-ranging from 10% in the vagina to 25% in the Fallopian tubes-are immune cells. He also presented data that indicate that the expression of CD4, CCR5, and CXCR4 in the female reproductive tract vary over the menstrual cycle. CCR5 expression peaks around ovulation, then drops, while CXCR4 expression also peaks around ovulation but remains relatively elevated until menstruation. CD4 expression is highest during the luteal phase. In addition to menstrual changes in immune function, there are decreases in pathogen defenses in postmenopausal women. 28 Florian Hladik, of the Fred Hutchinson Cancer Research Center, added that there is a higher concentration of CCR5 in the cervix than the blood, and that epithelial cells have higher levels of expression than stromal cells. 29 Viral shedding is also an important aspect of the biology of the mucosa. Rupert Kaul, of the University of Toronto, compared viral shedding in the male and female genital tracts. In men, HIV shedding occurs in about 80% of cases, whereas only 67% of women have detectable virus in the genital tract. Viral load in the semen is almost always lower than in the blood, although the two measures are correlated. In both sexes, concurrent infection with another STI negatively impacts on viral load and the extent of immune control of HIV. For example, although the number of CD8 1 T cells remains constant during concurrent gonorrhea infection, the proportion of cells that produce interferon-gamma is reduced. He noted that the presence of functional CD8 1 T cells in the blood is not sufficient to protect from mucosal infection if they are absent in the mucosa. In this respect, it is interesting that HIVinfected sex workers were found to have more CD8 1 T cells in the blood than the cervix, while the reverse was true of uninfected sex workers. 30 Addressing viral shedding from a somewhat different perspective, Stephen Taylor, from the University of Birmingham in England, measured the degree of penetration into the semen of a variety of anti-HIV drugs. Both NNRTIs studied had lower concentrations in the semen than blood, but levels in both cases were still above those considered therapeutic. Of the NRTIs, lamivudine and zidovudine both concentrate in the semen relative to blood, while other NRTIs show similar concentrations in each compartment. The PIs were the most variable. Saquinavir does not accumulate to adequate levels in the semen, while indinavir, which has lower protein binding, has equivalent blood and semen concentrations. 31 Once a (presumably vaginal) microbicide is available (projected to occur in 2007 according to Polly Harrison of the Alliance for Microbicide Development 32 ), it will also be used rectally. Anal intercourse has traditionally been viewed as the domain of men who have sex with men (MSM). However, in terms of absolute numbers, seven times as many women in the United States engage in anal sex than MSM. 5 Bethany Young Holt, from UC Berkeley, reported that anal sex is practiced by college women with both steady (18%) and casual (5%) partners. 33 The rate may be even higher in societies where anal sex may be practiced as a method of contraception and/or to preserve virginity prior to marriage. For example, it was reported that 70% of women in Brazil engage in anal sex. 34 The need for a rectal microbicide is clearly pressing.
A substantial portion of the conference was devoted to understanding the rectal mucosa and the difficulties associated with developing a microbicide suitable for use with anal sex. Ronald Veazey, of the Tulane Regional Primate Research Center, pointed out that the vagina consists of several layers of squamous epithelium, while the rectum has only a single layer columnar epithelium. The rectum may have evolved immune function to capture antigens that have survived digestion. For example, microfold cells sample antigens and then present them to effector lymphoid tissues. Macaques can become HIV-infected after atraumatic rectal inoculation, which in turn leads to the loss of CD4
1 T cells in the rectum only 14 days af-ter infection, while CD4 1 T-cell numbers are still preserved in the blood. In addition, memory cells appear to be preferentially lost in the intestines compared to blood. 35 Veazey also suggested that early viral load is higher after rectal than intravenous inoculation, although audience members denied that they had ever seen this effect.
In summarizing the importance of a better understanding of rectal biology and immunity, Pat Reichenderfer, from the National Institute of Child Health and Development (NICHD), noted that 62% of HIV-positive women are infected by anal intercourse, that the blood and lymph systems are more closely apposed to one another than in the vagina, that all T cells in the rectum are activated, and that the vast majority of T cells are dual tropic. She emphasized the need to recognize major role of rectal transmission.
Clearly, the rectal mucosa consists of delicate, fragile tissue that is more susceptible to infection than the vagina. The obvious question is why there is any protection from infection at all. Only about 1 in 100 anal sex acts with an HIV-positive insertive partner leads to infection, compared to as many as 50 in 100 cases of infection after intravenous inoculation with HIV-infected material. 36 Why is the rate of infection so relatively low? It is even lower with vaginal sex, where only 1 in 1000 sex acts with an infected partner results in infection in the woman. 36 The vaginal, and to a somewhat lesser extent the rectal, mucosa clearly have protective activity against HIV. As yet there are no clear ideas as to what this might constitute, but if the mechanism of protection could be elucidated, it might be manipulated and used as a kind of microbicide.
Several as yet unanswered questions arise from the differences between vaginal and rectal mucosa. How exactly is virus transmitted across these barriers? Where does productive infection take place? Are the answers to these questions generalizable between the rectum and vagina? Will we need different agents and/or formulations for use in the vagina versus rectum?
Once satisfactory answers to these questions are discovered, researchers will need good models to test for anti-HIV efficacy and toxicity. Pat Reichenderfer, of the NICHD, summed up the needs and future directions well when she emphasized the need for multiple models to answer single and multiple questions. Microbicide formulations should be tested in vitro, ex vivo, and in vivo using, for example, microarrays, explant models and nonhuman primates, respectively, ideally before proceeding to phase 1 trials. There is also the urgent need for standardization of models to allow for clear comparisons of microbicide candidates, as well as the comparison of results generated by the models and in clinical trials, in the interests of validation.
Which is the best way to evaluate the effect of a microbicide on mucosa? Christine Mauck, from CONRAD, gave an overview of colposcopy (examination of the genital tract under magnification), noting that 80% of colposcopic findings are not visible to the naked eye. 37 Are these findings relevant? Roberta Black, from NIAID, observed that colposcopic findings do not correlate with clinical symptoms. 38 It is not yet known whether colposcopic findings increase the risk of HIV infection. Nevertheless, researchers recommend that colposcopy be included as a means of evaluating epithelial changes associated with microbicide use in clinical trials.
Microbicide formulation has historically not received as much attention as its importance warrants. Guy van den Mooter, from the University of Leuven in Belgium, presented evidence that vaginal fluids (from transudation, cervix, Bartholin's glands), vaginal pH, enzymatic activity, and the thickness of the vaginal epithelium all vary with menstrual stage and status (premenopausal vs. postmenopausal). For example, ovulation is associated with higher vaginal fluid volume, lower pH, and thicker epithelium than is menstruation. In addition, hydrophilic drugs are absorbed most easily during the luteal phase, when the epithelium is more porous. 39 All of these factors suggest that a microbicide may be differentially effective over different portions of the menstrual cycle.
Other obvious formulation factors affecting microbicide efficacy include hydrophilicity, spreadability, viscosity, and bioadhesion. The vaginal cavity is approximately 60 cm 2,39 (the rectum is much larger and open ended, posing far greater difficulties), and because it is not known which part of the genital tract is most susceptible to HIV infection (e.g., cervix vs. vagina), a microbicide will optimally cover the entire region. Two researchers used different methods to measure the degree of spread and coverage in the vagina. Kurt Barnhart, of the University of Pennsylvania Medical Center, used noninvasive magnetic resonance imaging to quantify the spread of a gel placed intravaginally using a standard applicator. Five minutes after application, the gel was concentrated near the cervix, but coverage was increased by time, somewhat more by ambulation and most effectively by intercourse, which resulted in essentially 100% coverage. The gel conformed to the shape of the vagina, and in half of all women tested, also migrated through the cervix into the upper genital tract, posing potential clinical implications that should be addressed by future studies. 40 David Katz, from Duke University, measured the distribution of two commercially available formulations, Advantage™ (Columbia Laboratories, Inc., Livingston, NJ) and Conceptrol™ (Ortho Pharmaceutical Corp., Rariton, NJ), using an endoscopic device inserted into the vagina. The spatial resolution of this technique allows measurement of gel down to a thickness of 30 mm, allowing the detection of bare spots and the determination of whether the formulation achieves uniform coating. He found that Advantage™ spreads more evenly than Conceptrol™, and both spread faster and further following ambulation. 41 Formulation might also depend on cultural factors. The use of vaginal tablets is already widespread in India and appears to be well accepted. 42 Perhaps the most successful kind of microbicide there would also be a tablet, although there are concerns about the degree of solubility and spread of microbicidal agents formulated in tablet form. Women who prefer to engage in so-called dry sex, in which vaginal suppositories are used prior to sex to dry out the vaginal mucosa, might not use a microbicide that provides lubrication or gives a feeling of wetness. The prevalence of dry sex in Johannesburg was reported at slightly less than 5% among commercial sex workers and more than one quarter of women visiting a family planning clinic. 43 Ensuring that people use microbicides once they become available is by no means a simple matter. Of course, the development of a safe and effective microbicide will be in vain if the product is not widely used. Several important factors will have an impact on the extent of use, among them acceptability, availability, and cost. Acceptability, as defined by Susan Newcomer from the National Institutes of Health (NIH), causes the product to be selected, and then used consistently and correctly. Factors associated with the microbicide formulation will play a major role. Women who have taken part in microbicide clinical trials thus far have noted that characteristics such as messiness or leakiness would discourage use on a regular basis.
Detectability may also play a role. Women in situations where insistence on the use of a condom is difficult or impossible may well require that microbicides, in addition to being safe and effective, are also undetectable. The formulation should thus share visual, olfactory, tactile, and gustatory characteristics of normal vaginal secretions. In addition, if a microbicide detracts from sexual pleasure, it will certainly not be widely used. There is a growing realization that to ensure high microbicide use, they should actually enhance sexual pleasure. Different formulations may be required to address the needs of women who want to become pregnant versus those who do not.
Use of microbicides will have a public health impact if used by HIV-infected women having sex with uninfected men. Peter Vickerman, of the London School of Tropical Health and Medicine, presented data generated by mathematical modeling of the potential impact of microbicides in a low-prevalence setting, Cotonou, Benin. Against a background of 3% population HIV prevalence, 12% of men use female sex workers (FSW); 41% of these FSW are HIVpositive and 9% of their clients are also HIV-positive. Several parameters were considered in the mathematical model. If one assumes that a microbicide were 50% efficacious against HIV, gonorrhea, and chlamydia would be used by 20% of women in half of sex acts where condoms were not used, and the availability of a microbicide led to a 10% reduction in the use of con-doms, there would be a reduction from 41% to 39% HIV positivity among FSW with a less than 1% reduction in HIV in other risk groups. This would lead to a decrease of 319 new infections in the whole population. But if a microbicide is more efficacious, and condom use is low before the introduction of a microbicide, the benefits of the microbicide increase dramatically. 44 Anna Foss, also from the London School of Tropical Health and Medicine, presented results from a mathematical model calculating the potential impact of a microbicide in the face of condom migration, defined as a switch at least in part from condom use to microbicides. Data are scarce on the prevalence of condom migration in clinical trials of microbicides, but the highest level of migration appears to have occurred among sex workers in Columbia, who reduced condom use from 95% to 78%. 45 Mathematical modeling can be used to calculate the break-even point, the amount of condom migration that can be tolerated before an increase in HIV incidence occurs. The break-even point is not dependent on the number of sex acts, number of sex partners, or the prevalence of HIV and other STIs. It is, however, dependent on the ratio of efficacy between the condom and microbicide, the consistency of condom use prior to microbicide introduction, and the consistency of microbicide use. For example, a 50% efficacious microbicide that is used in 40% of sex acts is better at preventing HIV infection than a 90% efficacious condom that is used in 20% of sex acts. The amount of condom migration that can be tolerated varies greatly with condom use prior to microbicide introduction. If premicrobicide condom consistency is only 30%, a 25% condom migration can be tolerated without increased risk. However, if premicrobicide condom consistency is 90%, only 3.6% condom migration can be tolerated. 45 The eventual impact of microbicides would also be enormously boosted by stimulating broader market interest. Polly Harrison, from the Alliance for Microbicide Development, reported that there are approximately 25 biopharmaceutical companies, 38 nonprofit research entities, 5 public sector entities worldwide, and 36 supportive research entities involved in microbicide development. There are at least 52 product leads, 2 or more different delivery devices, and at least 1 special formulation, but products are not moving through the development pipeline fast enough. She speculated that there might be an adverse effect on market motivation if microbicides focus on HIV as opposed to a variety of STIs. 32 As data presented by Charlotte Watts indicated, the public health and productivity savings resulting from the successful implementation of an efficacious microbicide are substantial, amounting to billions of dollars worldwide. 6 But there is also a considerable market for microbicides in the United States. Bethany Young Holt, from the UC Berkeley School of Public Health, presented the results of a questionnaire administered to male and female undergraduate and graduate students. As many as two thirds of women reported that they would buy and use a microbicide, with likelihood of use increasing as the spectrum of activity (i.e., against other STIs or pregnancy) increased. 33 In addition, microbicides that have no spermicidal activity might be able to overcome some religious and social obstacles to their use. A survey conducted by the Boston Consulting Group indicates that pharmaceutical companies are interested in entering the microbicide market, but only after foundations and academic researchers develop first-generation microbicides that prove promising. 46 In all, there are several issues that should be resolved to maximize the chances that microbicides will decrease the incidence and prevalence of HIV worldwide. First and foremost is the need for a safe, effective pharmacologic agent that is effective not only against HIV but also optimally against a range of STIs that in themselves can enhance the transmission of HIV. It will be important that this agent does not cause irritation or ulceration, and it may prove necessary to develop entirely different formulations that fulfill these requirements for use intravaginally vs intrarectally. The discovery of such a pharmacologic agent(s) will likely be assisted by an improved understanding of critical events in the life cycle of HIV, especially those events that occur prior to viral integration into the host genome.
Each new potential microbicide will need to be tested thoroughly in vitro and in vivo before proceeding to clinical trials. In vitro and in vivo models should be validated, standardized, and optimized to answer the particular research questions being addressed. Practical and ethical issues surrounding the conduct of clinical trials are receiving increasing attention. The concerns of developing nations regarding the conduct of clinical trials in their communities, rather than in the developed world, should be addressed. While those settings are considered best because of the high rate of HIV and STIs, Sharon Hillier's observation of the surprisingly high rate and recurrence of STIs in the United States 22 suggest that there may be a role for clinical trials here.
The potential of microbicides to reduce the HIV epidemic warrants increased public and private spending. Lilani Kumaranayake, of the London School of Hygiene and Tropical Medicine (whose talk was presented by Charlotte Watts), predicts that low-and middle-income countries will primarily have access to microbicides through the public and social sectors, while in the industrial world, availability will be via private sector. A role for the public sector can be justified because the market system fails to take into account the potential benefits of a particular product to society, and does not address poverty or gender inequality (i.e., who has access to buying a particular product). 47 In order for maximal microbicide benefit, planning should begin now to address difficult issues surrounding distribution and optimized use.
CONCLUSION
There is a pressing need to find effective anti-HIV agent that is safe and nonirritating, that can be placed in a formulation that is undetectable to sex partners, and that effectively coats the entire surface of the vagina. More challenging is the development of a rectal microbicide. A more complete understanding of the vaginal and rectal mucosa, as well as the mechanisms governing mucosal HIV transmission, will probably speed the development of a maximally effective product. Candidate microbicides should be tested preclinically in in vitro, ex vivo, and in vivo models that predict clinical efficacy. Issues associated with the manufacture and distribution of a microbicide are complicated and should be addressed now. The development of a microbicide will require a concerted effort on several fronts, but with no means of eradicating the virus or even reliably ensuring life-long, symptom-free survival, the rewards of an effective microbicide will be worth the effort.
